EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY

Depressive Symptoms Clinical Trial

— SAMEUP  

Official title:

DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY OF SAMEUP IN SUBJECTS CHARACTERIZED BY MILD TO MODERATE DEPRESSION SYMPTOMS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03932474
• Other study ID #: SAMEUP
• Status: Completed
• Phase: N/A
• Start date: September 17, 2018
• Est. completion date: November 20, 2018

Study information

• Verified date: April 2019
• Source: Nutrilinea srl
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision) diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale.

Description:

Depression is a common condition of low mood and aversion to activity that can affect a person's thoughts, behaviour, tendencies, feelings, and sense of well-being.

Several literature findings suggest that an oral combination of the two food supplements SAMe (S-adenosyl-L-methionine) and probiotic Lactobacillus plantarum might be favourable in relieving some of symptoms of depression, particularly in the mild to moderate forms of this condition. This double blind placebo controlled clinical study aims to evaluate this hypothesis. In particular, the primary objective is to assess, versus placebo, the efficacy of SAMEUp in improving the overall symptomology of depression after 6 weeks of treatment. Subjects with mild to moderate depression were identified according to ICD-10 diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale.

SAMEUp, the investigational food supplement, is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU, already notified to the Ministry of Health as food supplement.

Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are indistinguishable.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: November 20, 2018
• Est. primary completion date: November 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Written informed consent, personally signed and dated by the subject.

2. Males and females, aging 18-60 years old (limits included).

3. Diagnosis of mild to moderate recurrent depressive disorder according to the ICD-10 / F33 criteria (World Health Organization, 2004).

4. Subject who, having completed the Z-SDS depression questionnaire, has a raw score between 41 and 55 (including limits).

5. Subject able to comprehend the full nature and purpose of the study, available to cooperate with the Investigator and to comply with the requirements of the entire study.

Exclusion Criteria:

1. Pregnant or breast-feeding woman.

2. Subject with one or more psychiatric disturbances, such as: alcoholism, substance abuse or dependency disorder, bipolar disorder, schizophrenia, or other personality disorder.

3. Subject with known or potential hypersensitivity to any ingredient in the study product.

4. Subject in treatment with psycholeptic drug, such as: antipsychotics, anxiolytics, hypnotics and sedatives.

5. Subject who has taken during the 2 weeks prior to inclusion, who is currently taking or plans to take other orally administered food supplements except the study product. Only multivitamins, salts and trace elements are accepted

Related Conditions & MeSH terms

• Depression
• Depressive Symptoms

Intervention

Combination Product:
• SAMEUp
One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.

Other:
• Placebo
One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet

Locations

Country	Name	City	State
Italy	Hippocrates Research	Genoa

Sponsors (2)

Lead Sponsor	Collaborator
Nutrilinea srl	Hippocrates Research

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Depression Scale	6 weeks
Secondary	Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the total score of the Zung's Self-Rating Depression Scale	2 weeks
Secondary	Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the core depressive factor of the Zung's Self-Rating Depression Scale.	2 weeks
Secondary	Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the core depressive factor of the Zung's Self-Rating Depression Scale.	6 weeks
Secondary	Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the cognitive factor of the Zung's Self-Rating Depression Scale.	2 weeks
Secondary	Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the cognitive factor of the Zung's Self-Rating Depression Scale.	6 weeks
Secondary	Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the anxiety factor of the Zung's Self-Rating Depression Scale.	2 weeks
Secondary	Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the anxiety factor of the Zung's Self-Rating Depression Scale.	6 weeks
Secondary	Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the somatic factor of the Zung's Self-Rating Depression Scale.	2 weeks
Secondary	Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the somatic factor of the Zung's Self-Rating Depression Scale.	6 weeks
Secondary	Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to two treatment-week of the total score of the Zung's Self-Rating Anxiety Scale.	2 weeks
Secondary	Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale	Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Anxiety Scale.	6 weeks
Secondary	Improvement in the insomnia condition evaluated through the Insomnia Severity Index	Absolute change from baseline to two treatment-week of the total score of the Insomnia Severity Index.	2 weeks
Secondary	Improvement in the insomnia condition evaluated through the Insomnia Severity Index	Absolute change from baseline to six treatment-week of the total score of the Insomnia Severity Index.	6 weeks
Secondary	Improvement in IBS (Irritable Bowel Syndrome) symptoms evaluated through the IBS questionnaire	Absolute change from baseline to two treatment-week of the total score of the IBS questionnaire.	2 weeks
Secondary	Improvement in IBS symptoms evaluated through the IBS questionnaire	Absolute change from baseline to six treatment-week of the total score of the IBS questionnaire.	6 weeks
Secondary	Improvement in the overall health status as measured by the EQ-5D-3L questionnaire	Absolute change from baseline to two treatment-week of the EQ-5D-3L questionnaire.	2 weeks
Secondary	Improvement in the overall health status as measured by the EQ-5D-3L questionnaire	Absolute change from baseline to six treatment-week of the EQ-5D-3L questionnaire.	6 weeks
Secondary	Evaluation of the patient's satisfaction grade	Subject's satisfaction grade at the end of the treatment.	6 weeks
Secondary	Incidence of adverse events described as per frequency and relationship with the study product	Adverse events occurrence during the study	6 weeks